e-Drug3D

1818

VELPATASVIR

INN
VELPATASVIR

cas 1377049-84-7

CLASS

ANTIINFECTIVES
HEPATITIS C VIRUS (HCV) NS5A INHIBITOR

ROUTE (list)

ORAL

ATC code

J05AP55
J05AP56

PK parameters

Tmax 3 HOUR
PPB 99.5 PERCENT
t1/2 15 HOUR

Solubility

PRACTICALLY INSOLUBLE IN WATER ABOVE PH 5

Target

TARGET NS5A

DrugCentral

Genome polyprotein UNIPROT P26663

Genome polyprotein UNIPROT P27958

Download SDF file

Carbamic acid, N-[(1R)-2-[(2S,4S)-2-[5-[1,11-dihydro-2-[(2S,5S)-1-[(2S)-2-[(methoxycarbonyl)amino]-3-methyl-1-oxobutyl]-5-methyl-2-pyrrolidinyl][2]benzopyrano[4',3':6,7]naphth[1,2-d]imidazol-9-yl]-1H-imidazol-2-yl]-4-(methoxymethyl)-1-pyrrolidinyl]-2-oxo-1-phenylethyl]-, methyl ester

Formula:
C49H54N8O8

Calculated chemical properties:

MW 883.00
NB_atoms 65
XLogP 7.73
PSA 179.744
NB_HD 4
NB_HA 16
fsp3 0.39
Lipinski(0=no;1=yes) 0

FDA
NDA 208341 (pdf not found) INN (SOFOSBUVIR ; VELPATASVIR) EPCLUSA (GILEAD SCIENCES INC) APPROVAL= AP YEAR= 2016
NDA 209195 (pdf not found) INN (SOFOSBUVIR ; VELPATASVIR ; VOXILAPREVIR) VOSEVI (GILEAD SCIENCES INC) APPROVAL= AP YEAR= 2017
NDA 214187 (pdf not found) INN (SOFOSBUVIR ; VELPATASVIR) EPCLUSA (GILEAD SCIENCES INC) APPROVAL= AP YEAR= 2021